Financial OutlookBTSG is anticipated to see mid- to high-teens percentage adjusted EBITDA growth in 2026, indicating a strong future financial outlook.
Future Growth PotentialBTSG remains well-positioned to generate significant EBITDA growth driven by new limited distribution drug wins and upcoming generic conversions.
Pharmaceutical PerformanceMomentum in Pharmacy Solutions is seen as a key positive, sustaining over 25% revenue growth for eight consecutive quarters.